How To Profit In A $29 Billion “New Biotech” Sector

What few knew at the time – and what researchers are thankfully looking into now – is how effective these substances can be in addressing a multitude of emotional, mental, and physical disorders and illnesses.

Research and Trial Results Are Beyond “Promising”

And research has really ramped up since 1980 – no less than 700 scholarly papers were published last year.

Top-tier, world-class institutions are heavily into psychedelics research. For instance, John Hopkins, NYU, and Imperial College London are funding programs to study the efficacy of using psilocybin, lysergic acid diethylamide (LSD), and MDMA (3,4-methylenedioxymethamphetamine) as treatment options for those struggling with their mental health.

A few recent studies in particular have captured my attention. Not only do they represent hope for suffering people, but they’ve sent dollar signs dancing in front of my eyes – more about that in a second.

In 2017, the Multidisciplinary Association for Psychedelic Studies (MAPS) was granted Breakthrough Therapy Designation for MDMA-Assisted Psychotherapy for PTSD, on Special Protocol Assessment for Phase III clinical trials. Breakthrough Therapy is a special U.S. Food and Drug Administration designation that accelerates the development of drugs with the potential to leapfrog existing treatments.

Early this week, The New York Times reported results of the MAPS-sponsored MDMA-assisted therapy study. The results found that 88% of those taking the MDMA-assisted treatment experienced a clinically significant reduction in symptoms. In fact, 67% of them no longer qualified for a PTSD diagnosis after three MDMA-assisted therapy sessions, compared to just 32% in the placebo group.

Barring any change in the trajectory of the research, we could see FDA approval of MDMA to treat PTSD in the relatively near future – with approval for psilocybin, the hallucinogenic compound found in many “magic mushrooms,” to treat various conditions, following that.

Jennifer Mitchell, a neuroscientist at the University of California, San Francisco, and a researcher involved with the PTSD study I talked about earlier, said, “this is a wonderful, fruitful time for discovery because people are suddenly willing to consider these substances as therapeutics again, which hasn’t happened in 50 years.”

This Has Multibillion-Dollar Real World Impact

For me, psychedelics are so alluring because the potential is widespread, impactful, and easy to quantify. We’re talking about potential treatments for mental health disorders such as PTSD, treatment-resistant depression, drug and alcohol abuse, eating disorders, and end-of-life anxiety.

View single page >> |

Disclaimer: Any performance results described herein are not based on actual trading of securities but are instead based on a hypothetical trading account which entered and exited the suggested ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.